NCT00765947View on ClinicalTrials.gov

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Essential Hypertension ( Mild to Moderate)
Interventions
DRUG

Aliskiren

Aliskiren 150 or 300 mg

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 12.5 or 25 mg

DRUG

Amlodipine

Amlodipine 5 or 10 mg

Trial Locations (4)

Unknown

Investigative Site, Paris

Investigative Site, Budapest

Investigative Site, Bucharest

Investigative Site, Bratislava

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00765947 - Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension | Biotech Hunter | Biotech Hunter